If the market pulls back, this will too. But we are at a level of support, so low volatility entry will allow us to manage the risk on this trade better. Breaking that support, we would close the trade.
This is a Bullish indicator signaling CORT's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron's A.I. dvisor identified 48 similar cases where CORT's MACD histogram became positive, and 42 of them led to successful outcomes. Odds of Success: 88%. Current price $30.80 is above $27.05 the highest support line found...
U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214
announced today that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a decision upholding the validity of all claims of U.S. Patent No. 10,195,214, “Concomitant Administration of Glucocorticoid Receptor Modulators...
Only an idea.
Industry ranked 37 in biotech. 3b market cap.
Big buy happened.
Current ratio of debt coverage is 10. :)
Modest growth 6% of ROE Q/Q: :| compared to others
Current volume trend is above normal, but 20day volume is below. so wait to see.
The dip is coming and then a run up.
Double bottom in RSI is bullish.
Hey traders, CORCEPT THERAPEUTICS is in a fake bearish move with low sell volume executed and a water carrier with strong shadow of buyers. In the TIMEFRAME M1 we can see a mini marubozu bull with a low purchase volume. Strong potential for breakout the price of going on its last precedent higher after. See if the buyers want to breakout the volume to get over the...
Over the last three days, Tickeron A.I.dvisor has detected that CORT's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring...
Gains occurring during an ongoing court hearing regarding the validity of its patent for Korlym, according to a Bloomberg headline. Corcept has been in a battle with Teva for its patent for Korlym, a treatment for Cushing’s syndrome approved by the FDA in 2012.
The fundamentals
While a stock’s fundamentals are not of great importance in swing trading, it’s good we consider a little of it to get an overview of the situation in the company at the moment.
The company’s fundamentals are not doing poorly at the moment. With 115.558 million shares outstanding and trading at $18.96, the market capitalization is about $2.195...
CORT BEAT EARNINGS Has Strong Buy Signal and Some analysts think it will hit $16
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are...
By no means has the sell off stopped; in the next few days, there should be another big drop;
if we manage a move outside the blue resistance (top), then we will begin a new structure; however, it is likely that we will bounce straight down from it
